Vanda Pharmaceuticals reported October 28 that revenue for the quarter ended September 30 rose 24% from a year earlier to $69.8 million. Its net loss was $22.6 million, unchanged from the third quarter of 2025.
The Washington-based drugmaker said operating expenses reached $93.3 million, up 7% from a year earlier but down 18% from the preceding quarter. Its second-quarter net loss had been $62.5 million.
Fanapt sales totaled $38.8 million, while Hetlioz contributed $21.7 million. Vanda said roughly $7 million of Hetlioz revenue came from orders shipped June 29 that arrived July 1 and were recognized in the third quarter. That timing matters when comparing consecutive quarters.
Cash, cash equivalents and marketable securities totaled $140.5 million at September 30, down $29.5 million during the quarter.
Vanda said it now expects full-year 2026 revenue above $240 million. That figure is management's outlook; the company reported $172.1 million in sales through September.
Sources - Vanda Pharmaceuticals quarterly results via PR Newswire: https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-third-quarter-2026-financial-results-302922677.html